Hutchmed (China) Limited Exercise of Share Options by a Director (4948I)
07 Août 2023 - 10:30AM
UK Regulatory
TIDMHCM
RNS Number : 4948I
Hutchmed (China) Limited
07 August 2023
Exercise of Share Options by a Director
Hong Kong, Shanghai & Florham Park, NJ - Monday, August 7,
2023: HUTCHMED (China) Limited ("HUTCHMED" or the "Company")
(Nasdaq/AIM: HCM, HKEX: 13) today announces that it has issued a
total of 3,000,000 ordinary shares of US$0.10 each ("Ordinary
Shares") following the exercise of share options by Dr Weiguo Su,
Executive Director, Chief Executive Officer and Chief Scientific
Officer, at an exercise price of GBP1.97 per Ordinary Share on
August 7, 2023 (the "Exercise of Options").
Following the Exercise of Options, Dr Su is beneficially
interested in 5,000,000 Ordinary Shares (Note 1) and 632,505
American Depositary Shares ("ADSs") (Note 2) , representing 0.94%
of the current issued share capital of the Company.
Notes:
1. 5,000,000 Ordinary Shares included (i) 3,000,000 Ordinary
Shares currently held by Dr Su, and (ii) share options for
2,000,000 Ordinary Shares granted under Share Option Scheme
2. 632,505 ADSs included (i) 143,518 ADSs currently held by Dr
Su, (ii) share options for 395,442 ADSs granted under Share Option
Scheme and (iii) 93,545 ADSs as beneficiary of a trust under long
term incentive plan.
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
---------------------------------- ------------------------------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director, Chief Executive Officer and Chief Scientific
Officer
---------------------------------- ------------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
---------------------------------- ------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
------------------------------------------------------------------------------------------------------------
a) Name HUTCHMED (China) Limited
---------------------------------- ------------------------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
---------------------------------- ------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
------------------------------------------------------------------------------------------------------------
a) Description of the financial Ordinary Shares of US$0.10 each
instrument, type of instrument
Identification code DI ISIN: KYG4672N1198
---------------------------------- ------------------------------------------------------------------------
b) Nature of the transaction Exercise of share options for 3,000,000 Ordinary Shares on August 7,
2023 at exercise price
of GBP1.97 per Ordinary Share
---------------------------------- ------------------------------------------------------------------------
Price(s) Volume(s)
---------------------------------- ----------------------------------
GBP1.97 3,000,000
---------------------------------- ----------------------------------
c) Price(s) and volume(s)
---------------------------------- ---------------------------------- ----------------------------------
d) Aggregated information Aggregated volume: 3,000,000 Ordinary Shares
- Aggregated volume Price information: GBP5,910,000
- Price
---------------------------------- ------------------------------------------------------------------------
e) Date of the transaction 2023-08-07
---------------------------------- ------------------------------------------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ------------------------------------------------------------------------
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has approximately 5,000 personnel across
all its companies, at the center of which is a team of about 1,800
in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around
the world, with its first three oncology drugs now approved and
marketed in China. For more information, please visit:
www.hutch--med.com or follow us on LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
HUTCHMED's filings with the U.S. Securities and Exchange
Commission, on AIM and on HKEX. HUTCHMED undertakes no obligation
to update or revise the information contained in this announcement,
whether as a result of new information, future events or
circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 306 4490
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile) / bmiles@s oleburystrat .com
Solebury Strategic Communications
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
FTI Consulting 545 055 (Mobile) / HUTCHMED@fticonsulting.com
Asia - Zhou Yi, Brunswick +852 97 83 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure
Gordon +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGZGGRNNNGFZG
(END) Dow Jones Newswires
August 07, 2023 04:30 ET (08:30 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
